Publications

Cancer cell

Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.

10-01-2022

European urology open science

Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment.

01-01-2022

Nature communications

Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.

22-12-2021

Current oncology (Toronto, Ont.)

Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors.

20-12-2021

The Lancet. Oncology

mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial.

01-12-2021

European journal of cancer (Oxford, England : 1990)

Adjuvant treatment for melanoma in clinical practice - Trial versus reality.

01-11-2021

Proceedings of the National Academy of Sciences of the United States of America

Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response.

26-10-2021

European journal of cancer (Oxford, England : 1990)

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.

18-10-2021

Cancers

Hospital Variation in Cancer Treatments and Survival OutComes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands.

11-10-2021

Clinical cancer research : an official journal of the American Association for Cancer Research

Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4.

01-10-2021

Cancer immunology, immunotherapy : CII

Metabolic profiles of regulatory T cells in the tumour microenvironment.

01-09-2021

Annals of surgery

Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR: A Prospective, Single-arm, Open-label Phase II Trial.

01-08-2021

The American Journal of dermatopathology

Letter Regarding Editorial by Samuel Zagarella.

01-07-2021

European journal of cancer (Oxford, England : 1990)

Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!

01-07-2021

Annals of oncology : official journal of the European Society for Medical Oncology

Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma.

01-07-2021

European journal of cancer (Oxford, England : 1990)

The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis.

01-07-2021

Nature medicine

An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer.

01-07-2021

Journal of translational medicine

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy).

30-06-2021

Cancers

Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors.

05-06-2021

The Lancet. Oncology

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.

01-06-2021

Annals of oncology : official journal of the European Society for Medical Oncology

Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma.

01-06-2021

The Lancet. Oncology

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.

01-05-2021

Annals of internal medicine

Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort Study.

01-05-2021

European journal of cancer (Oxford, England : 1990)

Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma.

01-05-2021

The Lancet. Oncology

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.

01-05-2021

British journal of cancer

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF^V600-mutant advanced melanoma patients: a propensity-matched survival analysis.

01-05-2021

Nature medicine

COVID-19 vaccination: the VOICE for patients with cancer.

01-04-2021

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Reply to E. Hindié.

10-03-2021

British journal of cancer

First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF^V600-mutant advanced melanoma patients: a propensity-matched survival analysis.

01-03-2021

British journal of cancer

Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.

01-02-2021

American journal of clinical oncology

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status.

01-02-2021

Nature medicine

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.

01-02-2021

Nature medicine

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).

01-02-2021

Clinical cancer research : an official journal of the American Association for Cancer Research

Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public Workshop.

15-01-2021

Acta oncologica (Stockholm, Sweden)

Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls.

01-01-2021

Journal for immunotherapy of cancer

Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition.

01-01-2021

Journal for immunotherapy of cancer

Comprehensive analysis of cutaneous and uveal melanoma liver metastases.

01-12-2020

Journal of autoimmunity

Modulating the wayward T cell: New horizons with immune checkpoint inhibitor treatments in autoimmunity, transplant, and cancer.

01-12-2020

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.

20-11-2020

ESMO open

Lower risk of severe checkpoint inhibitor toxicity in more advanced disease.

01-11-2020

Annals of oncology : official journal of the European Society for Medical Oncology

ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee.

01-11-2020

Annals of oncology : official journal of the European Society for Medical Oncology

ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee.

01-11-2020

Journal of translational medicine

Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy).

07-09-2020

Nature communications

Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.

07-08-2020

Journal for immunotherapy of cancer

Rationalizing the pathway to personalized neoadjuvant immunotherapy: the Lombard Street Approach.

01-08-2020

Annals of oncology : official journal of the European Society for Medical Oncology

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy^☆.

01-08-2020

Journal for immunotherapy of cancer

Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up.

01-08-2020

Cancers

Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response.

27-07-2020

Nature medicine

Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.

01-07-2020

Melanoma research

Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM).

01-06-2020